Protocol for the Treatment of Metastatic Ewing Sarcoma

• Status: Active, not recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy, radiotherapy and maintenance therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Italian Sarcoma Group
• Treatments: Busulfan; Cyclophosphamide; Doxorubicin; Etoposide; Etoposide phosphate; Ifosfamide; Irinotecan; Isophosphamide mustard; Liposomal doxorubicin; Melphalan; Temozolomide; Vincristine

Criteria

Inclusion Criteria:

• Histologically proven Ewing's sarcoma

• Age ≤ 40 years

• No previous treatment

• Multiple skeletal metastasis or bone marrow infiltration , with/without lung/pleural metastasis

• Signed Informed Consent

Exclusion Criteria:

• Localized Ewing's sarcoma

• Any contraindications to the study treatment

• Female patients who not accept to use an effective birth control method.

• Pregnant or breast-feeding patients